Introduction
============

Prostate cancer (PCa) is the most prevalent cancer in the western world for men and the second most common cause of death in men worldwide ([@r1]). Long-term follow-up from the European Randomised Study of Screening for Prostate Cancer (ERSPC) has shown a significant reduction in PCa specific mortality applying prostate-specific antigen (PSA) based screening ([@r2]). This, next to the fact that PSA is a well-developed, easy to implement, and cheap test, made PSA testing the mainstay in the decision for further clinical workup (i.e., prostate biopsy). However, any choice of a PSA cut-off involves a trade-off between sensitivity and specificity. Lowering the PSA cut-off would improve test sensitivity, but also reduce specificity, leading to far more false-positive tests and unnecessary interventions. Additionally, many of the cancers detected may never become clinically evident, thereby leading to overdiagnosis and overtreatment ([@r3],[@r4]).

Other relevant pre-biopsy clinical information, next to the serum PSA level, has been incorporated into so-called risk calculators (RCs) to enable a more accurate assessment of a patient's individual PCa risk ([@r5]). A recent systematic review identified 127 unique RCs in the field of PCa. The conclusion was that RCs outperform PSA alone in avoiding unnecessary biopsies, that not all of the RCs have the ability to selectively identify those men at risk of having clinically significant PCa (csPCa) (defined as Gleason score ≥3+4) and that external validation studies and head-to-head comparisons are lacking ([@r6]). RCs are part of the European Association of Urology (EAU), European Society for Radiotherapy & Oncology (ESTRO), European Society of Urogenital Radiology (ESUR), and International Society of Geriatric Oncology (SIOG) joint guidelines on PCa screening and early detection ([@r5]) but it remains a matter of personal choice whether and/or which RC to use in one's daily clinical practice.

We aimed to address this lack of information by evaluating the performance (discrimination, calibration, and clinical impact) of the most well-known RCs developed to predict prostate biopsy outcome in a head-to-head comparison.

Methods
=======

Participants
------------

Our study cohort comprises of 8,649 men from ten independent contemporary cohorts (nine in Europe and one in Australia) who underwent a transrectal ultrasound (TRUS)-guided prostate biopsy between January 2007 and November 2015 ([*Table 1*](#t1){ref-type="table"} and Acknowledgements). The cohorts were unrelated to the RCs development. Pre-biopsy clinical data and the pathological biopsy results were obtained from electronic and paper medical charts. Data on age, previous negative biopsy, DRE (digital rectal examination; benign/suspicious), prostate volume (assessed by TRUS in mL), total PSA (tPSA), free PSA (fPSA), and biopsy outcome (PCa detected yes/no and Gleason grade) were collected for all men. Patients were included into the analyses if they met the aggregated criteria of all RCs: age between 50 and 89 years old, PSA \<50 ng/mL, prostate volume between 10 and 110 mL ([*Table S1*](#tS.1){ref-type="table"}). Participants in the study underwent a TRUS-guided biopsy according to the standard clinical practice used at each participating site, which was on average 12 cores \[interquartile range (IQR): 12--14\] per biopsy session in the European cohorts and 30 cores (IQR: 12--30) in the Australian cohort.

###### Overview of the included predictors per RC to discriminate men at risk for any PCa and csPCa

  Risk calculator                             PSA   Age   PV   DRE   Free PSA   Fam.   Race   Prev Bx   IPSS   SD
  ------------------------------------------- ----- ----- ---- ----- ---------- ------ ------ --------- ------ ----
  Risk calculator, any PCa                                                                                     
     ERSPC RPCRC                              \+          \+   \+                             \+               
     Finne                                    \+          \+   \+    \+                                        
     Chun                                     \+    \+         \+    \+                                        \+
     Karakiewicz                              \+    \+         \+    \+                                        
     PCPT 1.0                                 \+               \+               \+            \+               
     PCPT 2.0                                 \+    \+         \+               \+     \+     \+               
     PCPT 2.0 + freePSA                       \+    \+         \+    \+         \+     \+     \+               
     ProstataClass                            \+    \+    \+   \+    \+                                        
     Sunnybrook                               \+    \+         \+    \+         \+     \+               \+     
  Risk calculator, clinical significant PCa                                                                    
     ERSPC RPCRC                              \+          \+   \+                             \+               
     PCPT HG                                  \+    \+         \+               \+     \+     \+               
     PCPT 2.0                                 \+    \+         \+    +\*        \+     \+     \+               
     Sunnybrook                               \+    \+         \+    \+         \+     \+               \+     

Age in years. \*, Analysed PCPT 2.0 models with free PSA and without free PSA. csPCa, clinically significant prostate cancer; DRE, digital rectal examination suspicious or not; Fam, family history or not of prostate cancer; free PSA, free proportion of total PSA; IPSS, International Prostate Symptom Score (0--35); Prev bx, previous negative biopsy; PSA, prostate-specific antigen, in ng/mL; PV, prostate volume, in mL; SD, sample density (prostate volume/number of biopsy cores taken).

Statistical analysis
--------------------

Baseline characteristics of the study cohort are presented as median and interquartile range (M-IQR) or percentage for proportion type features. Missing data was imputed using Multivariate Imputation by Chained Equations (MICE) using only the values from the corresponding cohort and was imputed five times ([@r7]). Three parameters were completely missing in certain cohorts: fPSA (Den Bosch, Sydney, Breda), International Prostate Symptom Score (Den Bosch, Porto, Bordeaux, Munster, Paris, Hamburg, Rennes, Milan), and family history of PCa (Den Bosch, Porto, Bordeaux, Munster, Paris, Rennes). These missing values were imputed by using the complete information from the other cohorts in the imputation model. This strategy leads to more precise estimates of the predicted probabilities ([@r8]). After imputation, the probabilities were calculated on the basis of the predictions rules from each RC. Individual patient data was compared for men with csPCa and men without PCa using the Mann-Whitney test for continuous variables.

Risk calculators
----------------

For this meta-analysis we included seven well known RCs: Chun ([@r9]), ERSPC Rotterdam Prostate Cancer Risk Calculator RPCRC ([@r10]), Finne ([@r11]), Karakiewcz ([@r12]), ProstataClass ([@r13]), Prostate Cancer Prevention Trial (PCPT) 1.0 and 2.0 +/-- free-PSA ([@r14]), and Sunnybrook ([@r15]). The first six have been externally validated in over five studies ([@r6]). All RCs use PSA and DRE as a predictive factor, and the other predictors are displayed in [*Table 1*](#t1){ref-type="table"}. The RPCRC for initial and repeat biopsy ([@r16]) was adapted to the contemporary Rotterdam clinical setting ([@r17]). For each individual patient, the probabilities of having a biopsy detectable PCa and, if applicable, a csPCa, were calculated. The probabilities of the ProstataClass artificial neural network were obtained by sending a blinded database for PCa outcome to the ProstataClass developers (H. Cammann) ([@r13]). For uniform comparison between RCs men with a PSA above their advised cut-off for PSA (i.e., \>20 ng/mL) were included (157 men (2.2% of the total cohort). Four models were able to separately predict csPCa (RPCRC, PCPT 2.0 +/-- freePSA and Sunnybrook).

Comparison of risk calculator models
------------------------------------

The predictive accuracy (predicting PCa and csPCa) was quantified using the area under the curve (AUC) for the receiver operator characteristic (ROC) analysis ([@r18]). A multivariable meta-analysis was performed to pool the AUCs in predicting any PCa and csPCa. Within-study correlations of the AUCs were estimated using bootstrapping. To analyze statistically significant differences in the models and taking into account the between-study heterogeneity we subsequently estimated the probability that a model has the highest AUC in a subsequent validation study. We simulated 10,000 samples from the posterior distribution to estimate this probability ([@r19]). Calibration of the RCs was pooled and explored graphically using calibrations plots. For comparison, the per center sensitivity and specificity of detecting csPCa with applying a PSA cut-off ≥4.0 ng/mL was calculated and graphically displayed.

In addition, the clinical impact was assessed with decision curve analysis (DCA) and clinical impact curves. DCA represents the net benefit ratio, which weighs the benefits (detecting cancer) versus the harms (unnecessary biopsy) over a range of thresholds ([@r20]). Clinical impact curves show the estimated number who would be declared eligible for biopsy for each risk threshold and show the proportion of those who are cases (overall PCa and csPCa) ([@r21]). In addition, to show the potential of multivariate risk stratification when adapting to, for example, one's own hospital data, we calculated net benefit after calibration of each of the 4 models predicting csPCa using the largest clinical cohort in our series (Den Bosch; N=2,053). Analyses were performed using R statistical package, version 3.3.1, R Foundation for Statistical Computing, Vienna, Austria.

Results
=======

Of the total of 8,649 men 7,119 men (83.2%) were included in analyses. Median age was 65 years old, median PSA 6.9 ng/mL, median prostate volume 45 mL (as evaluated by TRUS) and 1,496 men (21%) underwent a previous biopsy ([*Table 2*](#t2){ref-type="table"}). PCa was diagnosed in 3,458 of 7,119 patients (48%) and 1,784 (25%) men had csPCa. PCa patients were older (median age: 65 *vs.* 64 years for non PCa patients, P\<0.001), had smaller prostate glands (41 *vs.* 50 mL, P\<0.001), and higher PSA (6.7 *vs.* 7.0 ng/mL, P\<0.001) ([*Table 3*](#t3){ref-type="table"}).

###### Baseline characteristics of the independent cohorts

  Cohort, city    N of cases (%)   Age, M-IQR      PSA, M-IQR        Abnormal DRE, N (%)   Previous Bx, N (%)   Any PCa, N (%)   csPCa, N (%)
  --------------- ---------------- --------------- ----------------- --------------------- -------------------- ---------------- --------------
  Porto\*, PT     568 (7.9)        66 \[61--70\]   6.6 (4.8--8.9)    243 \[43\]            73 \[13\]            235 \[41\]       164 \[29\]
  Bordeaux, FR    1,568 (21.8)     65 \[61--69\]   7.0 (5.4--9.5)    616 \[39\]            202 \[13\]           845 \[54\]       370 \[24\]
  Paris, FR       116 (1.6)        65 \[60--71\]   4.4 (3.4--5.7)    38 \[33\]             16 \[13\[            66 \[59\]        25 \[24\]
  Rennes, FR      218 (3.0)        62 \[58--68\]   4.5 (3.4--5.8)    135 \[62\]            34 \[16\]            128 \[59\]       41 \[20\]
  Milan, IT       715 (9.9)        65 \[59--70\]   6.1 (4.4--8.6)    128 \[18\]            246 \[34\]           281 \[38\]       135 \[18\]
  Hamburg, DU     270 (3.8)        68 \[62--71\]   6.6 (4.6--9.5)    74 \[27\]             101 \[37\]           143 \[52\]       86 \[31\]
  Munster, DU     513 (7.1)        63 \[59--69\]   5.2 (4.1--6.4)    59 \[12\]             211 \[41\]           253 \[49\]       213 \[42\]
  Den Bosch, NL   2,053 (28.5)     64 \[60--69\]   7.9 (6.1--11.0)   566 \[28\]            428 \[21\]           847 \[41\]       368 \[18\]
  Breda, NL       644 (9.2)        66 \[62--71\]   9.4 (6.9--13.5)   219 \[32\]            157 \[24\]           298 \[47\]       124 \[20\]
  Sydney, AU      534 (7.4)        65 \[58--69\]   5.7 (4.1--8.3)    206 \[39\]            28 \[5\]             362 \[68\[       258 \[48\]
  Total           7,119            65 \[60--69\]   6.9 (5.1--9.6)    2,284 \[32\]          1,496 \[21\]         3,458 \[48\]     1,784 \[25\]

\*, given their similar protocol, the 65 patients from Évora were included in the Porto cohort. Bx, biopsy; csPCa, clinically significant prostate cancer; DRE, digital rectal examination; M-IQR, median and interquartile range.

###### Clinical characteristics of men with csPCa compared with men without PCa and lrPCa

  Variable                  No PCa, 3,741 (52%)   lrPCa, 1,674 (23%)    csPCa, 1,784 (25%)
  ------------------------- --------------------- --------------------- ---------------------
  Age at biopsy (years)     64 \[59--68\]         65 \[60--69\]         67 \[62--72\]
  Total PSA (ng/mL)         6.7 \[5.0--9.2\]      6.6 \[5.0--9.0\]      7.4 \[5.4--11.6\]
  Free PSA rati             0.16 \[0.12--0.21\]   0.14 \[0.10--0.18\]   0.12 \[0.08--0.16\]
  Abnormal DRE              673 \[18\]            559 \[33\]            1,036 \[58\]
  PV (mL)                   50 \[38--66\]         41 \[31--55\]         39 \[30--50\]
  Positive family history   594 \[16\]            319 \[19\]            347 \[20\]
  IPSS/AUA                  3 \[1--9\]            2 \[1--10\]           3 \[1--8\]
  Previous biopsy           977 \[26\]            316 \[19\]            198 \[11\]
  Number of cores           12 \[12--15\]         12 \[12--14\]         12 \[12--16\]

Data are shown as median \[IQR\] or number \[%\]. csPCa, clinically significant prostate cancer; IPSS, International Prostate Symptom Score; IQR, interquartile range; lrPCa, low risk prostate cancer; PV, prostate volume.

In predicting any PCa no particular RC stood out and the pooled area under the ROC-curve (AUC) ranged between 0.64 and 0.72 ([*Figure 1*](#f1){ref-type="fig"}) with Finne having the highest AUC. Substantial heterogeneity in the AUC was found between the different cohorts (range I^2^, 66--89%). In predicting csPCa the ERSPC RPCRC had the highest pooled AUC of 0.77 (95% CI: 0.73--0.80; [*Figure 1*](#f1){ref-type="fig"}). After repeating this comparative analysis 10,000 times the ERSPC RPCRC had the highest probability (89%) of having the highest AUC. The probabilities of having the highest AUC in our study cohort were 6%, 3%, and 2% for PCPT 2.0 + freePSA, PCPT 2.0, and Sunnybrook RCs respectively.

![Meta-analysis of the pooled area under the curve (AUC) and 95% CI of various PCa risk calculators to discriminate men diagnosed with any prostate cancer (above) and clinically significant PCa (below). CI, confidence interval; PCa, prostate cancer.](tau-07-01-18-f1){#f1}

The calibration plots for those RCs predicting csPCa for the pan-European data set (including all cohorts except Sydney, Australia; n=6,665) are displayed in [*Figure 2*](#f2){ref-type="fig"}. Three models underestimated the probability of csPCa, while the ERSPC RPCRC was more accurate at low probabilities and mainly overestimated at probabilities \>10%. [*Figure S1*](#fS.1){ref-type="fig"} displays the decision curves and clinical impact plots per cohort applying the 4 RCs predicting csPCa. Overall the ERSPC RPCRC has the highest net benefit followed by the PCPT 2.0. Clinical impact is negligible to small starting at probabilities \>10% for detecting csPCa. [*Figure S2*](#fS.2){ref-type="fig"} displays the differences in sensitivity and specificity of the PSA test (cut-off ≥4.0 ng/mL) per center. Sensitivity and specificity range from 76% to 98% and 4% to 44% respectively. [*Table 4*](#t4){ref-type="table"} shows net benefit when each of the 4 RCs are calibrated. At a 4% threshold for csPCa using the ERSPC RPCRC the number of biopsies can be reduced by 32% while keeping a 95% sensitivity for detecting csPCa. Reduction and sensitivity are 8% and 99% for PCPT2.0 + freePSA, 16% and 97% for PCPT 2.0, and 25% and 95% for Sunnybrook.

![Pooled calibration plots for clinical significant prostate cancer using ERSPC RPCRC (A), Sunnybrook (B), PCPT 2.0 (C) and PCPT 2.0 + freePSA (D) risk calculators in the nine European cohorts. CI, confidence interval; free PSA, free proportion of total prostate-specific antigen.](tau-07-01-18-f2){#f2}

###### Net benefit, biopsy reduction of and missed prostate cancers with the use of four risk calculators predicting clinical significant prostate cancer at a 4% and 10% risk threshold in the Den Bosch cohort

  Risk calculator         Biopsy reduction (% of total biopsy)   Missed prostate cancers   Net benefit   
  ----------------------- -------------------------------------- ------------------------- ------------- -------
  Threshold 4%                                                                                           0.145
     ERSPC RPCRC          665 (32.4)                             118 (24.6)                17 (4.6)      0.150
     PCPT 2.0 + freePSA   162 (7.9)                              32 (6.7)                  3 (0.8)       0.147
     PCPT 2.0             319 (15.5)                             73 (15.2)                 12 (3.3)      0.145
     Sunnybrook           516 (25.1)                             105 (21.9)                20 (5.4)      0.145
  Threshold 10%                                                                                          0.088
     ERSPC RPCRC          1,202 (58.5)                           247 (51.6)                60 (16.3)     0.127
     PCPT 2.0 + freePSA   890 (43.4)                             216 (45.1)                61 (16.6)     0.103
     PCPT 2.0             957 (46.7)                             231 (48.2)                52 (14.1)     0.112
     Sunnybrook           1,164 (56.7)                           277 (57.8)                58 (15.8)     0.120

csPCa, clinically significant prostate cancer; PCa, prostate cancer.

Discussion
==========

In this head-to-head comparison of seven well-known RCs predicting prostate biopsy outcome it is shown that all RCs have a moderate to well discriminatory ability when predicting any PCa (AUCs ranging from 0.64 to 0.72). Those RCs that can selectively predict csPCa show AUCs in the range of 0.71 to 0.77 with small clinical benefit in this pan-European cohort of contemporary daily clinical practice and clinical study data. Adjusting calibration shows the added value of incorporating multivariable risk prediction tools next to clinical expertise in clinical decision making. These results confirm earlier analyses on the use of multivariable prediction tools ([@r6]) and considering the substantial harm related to overdiagnosis of low risk PCa ([@r3],[@r22]), the use of those RCs that selectively can predict csPCa is recommended.

The balance between benefit and harm of early detection of PCa is still a topic of ongoing debate. Due to the initiation of PSA screening in combination with TRUS guided systematic prostate biopsy the incidence of predominantly low risk PCa increased enormously in the 1990s. This eventually resulted in guidelines recommending no screening at all ([@r23]). However, with the available data from longitudinal studies and randomized PCa screening trials we currently have, the knowledge to improve the balance between harm and benefit recommendations have changed to using shared decision making with an individual approach towards how to screen best ([@r24]).

While both discrimination and calibration are important statistics to evaluate performance of a prediction tool we must note that discrimination cannot be easily improved while calibration can ([@r6]). An example of potentially adjusting calibration to a particular setting is shown in ([@r25]) where a model was first tested using part of the available data (calibration phase) where subsequently performance was assessed in the rest of the data (validation cohort). Based on the wide calibration prediction intervals in the current analyses it is advisable to follow such an approach where the aim should be to assess moderate calibration on the basis of center specific retrospective data on prostate biopsy outcome with a minimum of 200 prostate cancers cases ([@r26]). Subsequently these center specific adjustments for the calculated probabilities could be incorporated, for example, in the RPCRC. It is in this context important to realize that when using a purely PSA based approach considerable variation in sensitivity and specificity also exists, as was shown in [*Figure S2*](#fS.2){ref-type="fig"}*,* something that is ignored in recommendations on applying a cut-off value to trigger prostate biopsy.

When predicting biopsy outcome, it must also be noted that especially the use of the multiparametric magnetic resonance imaging (mpMRI) in the detection of PCa and csPCa has increased considerably showing very promising results. However, while the mpMRI is advised to be used after a negative TRUS guided systematic prostate biopsy (often solely based on an elevated PSA level), the mpMRI is more and more used before the first biopsy ([@r27]). Previous analyses with the RPCRC have however shown that upfront risk stratification on the basis of easy (and cheap) to get relevant pre-biopsy information can avoid half of mpMRIs ([@r17]).

This study has some limitations. First, it is a retrospective study design using ten different cohorts from populations with different background risk and different referral patterns (daily clinical practice cohorts with the risk of selective outcome reporting and clinical study cohorts with predefined eligibility criteria) as reflected in the heterogeneity of our results. On the other hand, evaluating performance of these RCs in this pan-European setting can be seen as a strength and support their use in Europe. Second, we mainly used the original RCs which were virtually all developed in the 1990s. This implies that they do not use later developed biomarkers (e.g., PHI, PCA3, the 4K panel). All these biomarkers have shown to have additional predictive value when incorporated into a prediction model and as such might be able to positively influence results ([@r28]-[@r30]).

Finally, all RCs use as endpoint csPCa based on the original Gleason grading ([@r31]). It has been shown that the new Gleason grading system better reflects disease burden ([@r32]) as does the inclusion of cribriform growth patterns in the classification of Gleason 7 PCa ([@r16],[@r33]).

In conclusion, we performed the first head-to-head comparison of RCs predicting prostate biopsy outcome using a multicenter European and Australian population. No particular RC stood out in the discrimination of men with and without PCa. The ERSPC RPCRC showed highest discrimination when predicting clinically significant PCa. Net benefit in the available clinical cohorts was limited but can be increased by applying a simple calibration step. These outcomes support implementing next to clinical expertise a multivariable risk prediction tool before further workup (e.g., MRI and biopsy) in men suspicious for having a clinically significant PCa.

![Decision curve for the four models predicting clinically significant prostate cancer in all the individual cohorts (left panel) and clinical impact plots (right panel) for predicting clinical significant prostate cancer (csPCa) with the ERSPC RPCRC. Of the 1,000 patients, the black solid line shows the total number of men who would receive a biopsy for each risk threshold. The orange dashed line shows how many of those would be detected with any prostate and the black dashed line shows how many of those would be detected with csPCa. The space between the two dashed lines indicated the number of men with indolent PCa.](tau-07-01-18-fS.1){#fS.1}

![Sensitivity and specificity per study cohort of the biomarker PSA applying a cut-off for biopsy of ≥4.0 ng/mL and predicting the presence of clinically significant prostate cancer (defined as GS ≥7). PSA, prostate specific antigen; GS, Gleason score.](tau-07-01-18-fS.2){#fS.2}

###### Inclusion criteria of the different risk calculators

  RC              Age (years)   N of biopsy cores   PSA, ng/mL   Prostate volume
  --------------- ------------- ------------------- ------------ -----------------
  ERSPC RPCRC     50--74        ≥6                  \<50         10--110 mL
  Finne           55--67        ≥6                  --           --
  Chun            --            ≥10                 --           --
  Karakiewicz     --            ≥6                  \<50         --
  PCPT 1.0        \>55          ≥6                  --           --
  PCPT 2.0        \>55          ≥6                  --           --
  ProstataClass   \<89          ≥6                  \<25         --
  Sunnybrook      --            12                  \<50         --

PSA, prostate-specific antigen.
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